Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 11;10(1):67.
doi: 10.1186/s40959-024-00267-5.

Comparison of heart failure risk assessment tools among cancer survivors

Affiliations

Comparison of heart failure risk assessment tools among cancer survivors

Cheng Hwee Soh et al. Cardiooncology. .

Abstract

Background: Cancer survivors have an increased risk of incident heart failure (HF) attributable to shared risk factors and cancer treatment-induced cardiac dysfunction. Selection for HF screening depends on risk assessment, but the optimal means of assessing risk is undefined. We undertook a comparison of HF risk calculators among survivors.

Methods: In this study from the UK Biobank, cancer and HF diagnoses were determined based on the International Classification of Diseases (ICD)-10 code and non-cancer participants were included as controls. Participants' risk of incident HF was determined using the Heart Failure Association-International Cardio-oncology Society (HFA-ICOS), the Atherosclerosis Risk in Communities (ARIC-HF) and the Pooled Cohort Equations to Prevent Heart Failure (PCP-HF). The predictive performances of each were compared using the area under the curve (AUC).

Results: After propensity matching with age and sex, 9,232 survivors from breast cancer or lymphoma (mean age 59.9 years, 87.8% female), and 23,800 survivors from other cancer types (mean age 59.1 years, 85.8% female) were included in the analysis. The discriminative value for HFA-ICOS (AUC 0.753 [95%CI: 0.739-0.766]) and ARIC-HF (0.757 [95%CI: 0.744-0.770]) were similar, and superior to PCP-HF (0.717 [95%CI: 0.702-0.732]). The overall performance for each risk score was better among participants in other cancer types than those with breast cancer and lymphoma.

Conclusions: HFA-ICOS and ARIC-HF outperformed the PCP-HF among cancer- and non-cancer cohort, although all showed modest discrimination for incident HF to be applied to clinical practice. A cancer-specific HF prediction tool could facilitate HF prevention among survivors.

Keywords: Cancer; Heart failure; Prognosis; Risk assessment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The cumulative incidence plot of heart failure among UK Biobank participants
Fig. 2
Fig. 2
The cumulative incidence plot of heart failure among cancer survivors, stratified according to age range
Fig. 3
Fig. 3
The receiver operating characteristics curve for each CVD risk assessment tool in predicting heart failure incidence. CVD: Cardiovascular disease; ARIC-HF: Atherosclerosis Risk in Communities – Heart Failure; PCP-HF: Pooled Cohort Equations to Prevent Heart Failure; HFA-ICOS: Cardio-Oncology Risk Assessment.

Similar articles

References

    1. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in Heart failure. Circulation: Heart Fail. 2008;1:91–7. - PMC - PubMed
    1. Jones NR, Hobbs FR, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open. 2017;1:bjgpopen17X101013. - PMC - PubMed
    1. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk factors in Cardiovascular Disease and Cancer. Circulation. 2016;133:1104–14. - PMC - PubMed
    1. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Reviews Cardiol. 2015;12:547–58. - PubMed
    1. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945–60. - PMC - PubMed

LinkOut - more resources